Hepatocellular carcinoma is a kind of cancer that affects the liver. HCC consider the main reason for the great ratio of cancer deaths worldwide. In Europe and the United States, its occurrence is quickly elevating, due to the present epidemic of hepatitis C virus and nonalcoholic fatty liver disease cases. Patients with HCC have a prognosis that is impacted by many factors as tumor stage, with therapeutic choices only obtainable for patients who have been diagnosed early. Currently, the main effective therapy for HCC is considered surgery, which includes transplantation resection. Moreover, rates of recurrence are increased and in the long run duration, the chance of surviving is slim. Traditional cytotoxic chemotherapy has not been proven to be effective in giving clinical advantages or lengthy patients' survival with developed HCC. Cisplatin is considered one of the main medications used in the conventional treatment of several cancers in different organs. Latterly, many hopeful results of utilizing have been demonstrated cisplatin in the therapy of patients with HCC has developed, in addition, Doxorubicin has a wide range of anti-tumor properties. The importance of early discovery through surveillance programs cannot be overstated. Therefore, the assessment of alpha-fetoprotein (AFP) and ultrasound for patients at risk of developing HCC are recommended in HCC guidelines all around the world. Therefore, the treatment with cisplatin and doxorubicin significantly reduced the elevation in the levels of AFP in HepG-2 cells. Moreover, The findings showed that doxorubicin and cisplatin can inhibit HCC cell proliferation by enhancing hepatocyte function.